Navigation Links
Appointment of Mr. Kevin Buchi to Benitec Board
Date:4/11/2013

SYDNEY, April 10, 2013 /PRNewswire/ -- Benitec Biopharma Ltd (ASX: BLT), a biopharmaceutical company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), is very pleased to report that Mr. Kevin Buchi , CPA, has accepted an invitation to join the Company's Board of Directors. 

Mr. Buchi served as Chief Executive Officer of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO.

Mr. Buchi currently serves on the Board of Directors of Stemline Therapeutics, Inc., Forward Pharma A/S and Alexza Pharmaceuticals, Inc. Mr. Buchi has served on the Board of Directors of Lorus Therapeutics (Canada), Encysive Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc. and Mesoblast Limited (Australia). Mr. Buchi has served as a Member of the Life Sciences Advisory Board at Safeguard Scientifics, Inc.

Mr. Buchi originally trained as a synthetic organic chemist for the Eastman Kodak Company graduating from Cornell University with a Bachelor of Arts degree in chemistry. He holds a Master's degree in management from the Kellogg Graduate School of Management at Northwestern University and is a Certified Public Accountant. He resides in Pennsylvania in the United States.

Benitec Biopharma's Chairman, Mr. Peter Francis
'/>"/>

SOURCE Benitec Biopharma Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. National Honey Board Seeks Board Member Nominees: Appointments to be Made by United States Secretary of Agriculture
2. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
3. Store-A-Tooth™ Stem Cell Banking Announces Appointment of Dedicated Sales Representative in New England
4. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
5. PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
6. Mobility and Big Data Analytics Provider NuWare Announces the Appointment of Rohit Shyam as Chief Strategy & Marketing Officer
7. Store-A-Tooth™ Dental Stem Cell Banking Announces Appointment of Dedicated Representative in South Florida
8. Sequenom Announces Leadership Appointments
9. T1D Exchange Announces Appointment of Dana Ball as Chief Executive Officer
10. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
11. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Boston, MA (PRWEB) July 23, 2014 ... regenerative medicine transplant therapies are biological, but not ... trials may seem to treat them as if ... as well as unsanctioned studies that constitute “stem ... transplantation as an approach to developing new regenerative ...
(Date:7/22/2014)... D.C., June 22, 2014 Even within a phylum so ... is distinguished among other arthropods for its cruelty -- at ... Central America, the fly is a most predatory sort of ... cricket, deposits a smear of larvae, and leaves its wicked ... out. , None of this would be possible without ...
(Date:7/22/2014)... , July 22, 2014   BioTE Medical ... using natural, bio-identical hormone pellets, today announced the ... to the company.   Dr. Rouzier is joining the ...     Dr. Rouzier was residency trained ... and is a board certified emergency physician still ...
(Date:7/22/2014)... Wisconsin (PRWEB) July 22, 2014 ... in attendance at the 2014 NCSL International Workshop ... Booth #423 will feature CONDEC pressure instrumentation, OIML ... weights, and the new, customized sets, Essential Weights™. ... to promote cooperative efforts in solving the common ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2
... (CTI),(Nasdaq and MTA: CTIC) announced today that the ... Letter") from the Listing,Qualifications Staff (the "Staff") of ... not comply with Marketplace Rule 4350(i)(1)(C) when the,Company ... ("SMI"),and issued additional common shares to SMI shareholders. ...
... 26 Cardium Therapeutics (NYSE Alternext US: CXM) today ... from the Company,s Board of Directors. The resignation ... "We thank Dr. Simon for his service to ... the years ahead," stated Christopher J. Reinhard, Chairman and ...
... Increased 2 Percent to $15.0 Billion; Fourth Quarter 2008 ... Per Share Increased 38 Percent to $3.90; Fourth Quarter ... $0.912009 Total Revenue Expected to be in the Range ... Expected to be in the Range of $4.55 to ...
Cached Biology Technology:Cell Therapeutics Receives Additional NASDAQ Notification 2Cell Therapeutics Receives Additional NASDAQ Notification 3Cell Therapeutics Receives Additional NASDAQ Notification 4Cardium Announces Retirement of Director 2Cardium Announces Retirement of Director 3Cardium Announces Retirement of Director 4Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 2Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 3Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 4Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 5Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 6Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 7Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 8Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 9Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 10Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 11Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 12Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 13Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 14Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 15Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 16Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 17Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 18Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 19Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 20Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 21Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 22Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 23Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 24Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 25Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 26Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 27
(Date:7/22/2014)... challenges faced by researchers in modifying properties of nanomaterials ... simple technique, thanks to recent innovative studies conducted by ... Through the use of a simple, efficient and low ... research teams, led by Professor Sow Chorng Haur from ... Science, demonstrated that the properties of two different types ...
(Date:7/22/2014)... of a multinational, collaborative effort, researchers from the Icahn ... over 100 locations in the human genome associated with ... study published on any psychiatric disorder to date, conducted ... Nature , point to biological mechanisms and pathways that ... to treating the disorder, which has seen little innovation ...
(Date:7/22/2014)... in schoolyards that feature natural habitats and trees and ... and inattention, according to a University of Colorado Boulder ... such settings also provide stress-reducing benefits for youth, according ... & Place. The study is one of the ... between student access to green settings and stress. , ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Mount Sinai scientists and international team shed new light on schizophrenia 2Mount Sinai scientists and international team shed new light on schizophrenia 3Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 2Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 3
... 8, 2010 -- Conversion of sorghum grass to ethanol ... at Iowa State University examined 12 varieties of sorghum grass ... designed to test the efficiency of double cropping sorghum grass ... author of the report, Ben Goff, found that using sorghum ...
... 10, 2010 -- To keep soldiers in the battlefield healthy, ... bacteria in water. Current techniques for analyzing water ... to complete, according to Bart Lipkens of Western New England ... in Andover, Ma. They are working on an ...
... garden next spring and farmers sow in their fields ... stay healthy, and grow to yield bountiful harvests. It,s a ... encourage seeds to germinate earlier in the season, resist insects ... are the topic of an article in the current issue ...
Cached Biology News:Growing sorghum for biofuel 2
... 1 ( Abpromise for all tested applications). ... to KLH derived from within residues 1850 to ... (Note: the amino acid sequence is proprietary) ... Entrez Gene ID: 89796 ...
Na+/H+ exchanger, isoform NHE1....
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Biology Products: